Artificial intelligence-based image analysis in clinical testing: lessons from cervical cancer screening.

Journal: Journal of the National Cancer Institute
Published Date:

Abstract

Novel screening and diagnostic tests based on artificial intelligence (AI) image recognition algorithms are proliferating. Some initial reports claim outstanding accuracy followed by disappointing lack of confirmation, including our own early work on cervical screening. This is a presentation of lessons learned, organized as a conceptual step-by-step approach to bridge the gap between the creation of an AI algorithm and clinical efficacy. The first fundamental principle is specifying rigorously what the algorithm is designed to identify and what the test is intended to measure (eg, screening, diagnostic, or prognostic). Second, designing the AI algorithm to minimize the most clinically important errors. For example, many equivocal cervical images cannot yet be labeled because the borderline between cases and controls is blurred. To avoid a misclassified case-control dichotomy, we have isolated the equivocal cases and formally included an intermediate, indeterminate class (severity order of classes: case>indeterminate>control). The third principle is evaluating AI algorithms like any other test, using clinical epidemiologic criteria. Repeatability of the algorithm at the borderline, for indeterminate images, has proven extremely informative. Distinguishing between internal and external validation is also essential. Linking the AI algorithm results to clinical risk estimation is the fourth principle. Absolute risk (not relative) is the critical metric for translating a test result into clinical use. Finally, generating risk-based guidelines for clinical use that match local resources and priorities is the last principle in our approach. We are particularly interested in applications to lower-resource settings to address health disparities. We note that similar principles apply to other domains of AI-based image analysis for medical diagnostic testing.

Authors

  • Didem Egemen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Rebecca B Perkins
    Department of Obstetrics and Gynecology, Boston Medical Center/Boston University School of Medicine, Boston, MA, USA.
  • Li C Cheung
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
  • Brian Befano
  • Ana Cecilia Rodriguez
  • Kanan Desai
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
  • Andreanne Lemay
    NeuroPoly Lab, Institute of Biomedical Engineering, Polytechnique Montreal, Montreal, QC, Canada; Mila, Quebec AI Institute, Canada.
  • Syed Rakin Ahmed
    From the Athinoula A. Martinos Center for Biomedical Imaging (M.G., K.C., J.B.P., K.V.H., S.R.A., P.S., J.K.C.) and Department of Radiology (J.K.C.), Massachusetts General Brigham, 13th St, Building 149, Room 2301, Charlestown, MA 02129; Case Western School of Medicine, Cleveland, Ohio (M.G.); Harvard-MIT Division of Health Sciences and Technology, Cambridge, Mass (J.B.P., K.V.H.); Harvard Graduate Program in Biophysics, Harvard Medical School, Harvard University, Cambridge, Mass (S.R.A.); Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH (S.R.A.); and Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (C.D.F.).
  • Sameer Antani
    Computational Health Research Branch, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.
  • Jose Jeronimo
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Nicolas Wentzensen
  • Jayashree Kalpathy-Cramer
    Department of Radiology, MGH/Harvard Medical School, Charlestown, Massachusetts.
  • Silvia de Sanjosé
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Mark Schiffman